Expertise in
59
conditions

Dr. Rachit M. Kumar

Internal Medicine
Virginia Cancer Institute - Southside Regional
263 Medical Park Boulevard, Suite 200, 
Petersburg, VA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
17 Years of Experience
Expertise in
59
conditions
Virginia Cancer Institute - Southside Regional
263 Medical Park Boulevard, Suite 200, 
Petersburg, VA 

Overview

Rachit Kumar is a primary care provider, practicing in Internal Medicine in Petersburg, Virginia. He has been practicing medicine for over 17 years.

Dr. Kumar is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Thrombocytopenia, Dehydration, Pancreaticoduodenectomy, and Liver Embolization.

Dr. Kumar is board certified in (Internal Medicine, Medical Oncology), (Internal Medicine, Hematology), (Internal Medicine), and American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 92 peer reviewed articles and participating in 10 clinical trials. Dr. Kumar is currently accepting new patients.

Graduate Year

2009

Specialties

Internal Medicine

Licenses

Internal Medicine in ME

Board Certifications

(Internal Medicine, Medical Oncology)
(Internal Medicine, Hematology)
(Internal Medicine)
American Board Of Internal Medicine

Fellowships

Medstar Washington Hospital Center, Internal Medicine, Hematology & Oncology - 2017

Hospital Affiliations

Bon Secours Memorial Regional Medical Center
Henrico Doctors' Hospital
Cjw Medical Center
Bon Secours Memorial Regional Medical Center
Bon Secours St Marys Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Virginia Cancer Institute - Southside Regional
263 Medical Park Boulevard, Suite 200, Petersburg, VA 23805
Other Locations
Virginia Cancer Institute
7492 Right Flank Road, Mechanicsville, VA 23116

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2/Phase 3
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Other, Drug
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Enrollment Status: Available
Publish Date: June 04, 2026
Intervention Type: Drug
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

92 Total Publications

PMBB Geno-Pheno Toolkit: A suite of scalable, reproducible pipelines for cross-biobank association analyses.
PMBB Geno-Pheno Toolkit: A suite of scalable, reproducible pipelines for cross-biobank association analyses.
Journal: bioRxiv : the preprint server for biology
Published: August 01, 2026
Similar Doctors
Expertise in
7
conditions
Dr. Wally R. Smith
Internal Medicine
Expertise in
7
conditions
Dr. Wally R. Smith
Internal Medicine

Virginia Commonwealth University Health System Authority

1250 E Marshall St, 
Richmond, VA 
 (27.8 miles away)
804-828-9690
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wally Smith is a primary care provider, practicing in Internal Medicine in Richmond, Virginia. Dr. Smith is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Smith is currently accepting new patients.

Expertise in
19
conditions
Dr. Velimir A. Luketic
Internal Medicine
Expertise in
19
conditions
Dr. Velimir A. Luketic
Internal Medicine

Virginia Urology Center PC

9105 Stony Point Dr, 
Richmond, VA 
 (29.7 miles away)
804-828-4060
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Velimir Luketic is a primary care provider, practicing in Internal Medicine in Richmond, Virginia. He has been practicing medicine for over 44 years. Dr. Luketic is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Primary Biliary Cholangitis, Cirrhosis, Liver Failure, Cholestasis, and Liver Transplant. Dr. Luketic is currently accepting new patients.

Expertise in
13
conditions
Dr. Sherman D. Baker
Internal Medicine
Expertise in
13
conditions
Dr. Sherman D. Baker
Internal Medicine

VCU Health System Stony Point

9000 Stony Point Pkwy, 
Richmond, VA 
 (30.0 miles away)
804-327-3055
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sherman Baker is a primary care provider, practicing in Internal Medicine in Richmond, Virginia. Dr. Baker is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Baker is currently accepting new patients.

Frequently Asked Questions about Dr. Rachit M. Kumar

How do I make an appointment with Dr. Rachit M. Kumar?

You can book an appointment with Dr. Rachit M. Kumar by calling their office at 804-559-2489. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rachit M. Kumar a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rachit M. Kumar is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rachit M. Kumar specialize in?

While Dr. Rachit M. Kumar is a Internal Medicine, they have specific expertise in Lung Cancer, Thrombocytopenia, and Dehydration. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Rachit M. Kumar participate in research or clinical trials?

Yes. Dr. Rachit M. Kumar has published 92 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Rachit M. Kumar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rachit M. Kumar accept my insurance?

Dr. Rachit M. Kumar accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 804-559-2489 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
    View All 58 Advanced Conditions
    View All 140 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile